Adverum Biotechnologies, Inc. (LON:0HA3)
4.288
+0.069 (1.64%)
At close: Oct 31, 2025
Adverum Biotechnologies Revenue
Adverum Biotechnologies had revenue of $1.00M USD in the twelve months ending June 30, 2025. In the year 2024, Adverum Biotechnologies had annual revenue of $1.00M, down -72.22%.
Revenue
$1.00M
Revenue Growth
-72.22%
P/S Ratio
94.12
Revenue / Employee
$6.45K
Employees
155
Market Cap
68.70M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | -2.60M | -72.22% |
| Dec 31, 2023 | 3.60M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 7.50M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 134.89B |
| Unilever | 51.24B |
| HSBC Holdings | 43.13B |
| AstraZeneca | 41.24B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.03B |
Adverum Biotechnologies News
- 6 days ago - With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big - Seeking Alpha
- 7 days ago - ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders - Business Wire
- 8 days ago - Eli Lilly: Is Another Monster Quarter Coming - Seeking Alpha
- 9 days ago - Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM - Business Wire
- 9 days ago - $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) - PRNewsWire
- 10 days ago - Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders - PRNewsWire
- 10 days ago - Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections - Benzinga
- 10 days ago - Eli Lilly to buy gene therapy developer Adverum in about $262 million deal - Reuters